William Dalton

Johns Hopkins University

United States

Research Interests

Explore related searches

Professors in United States Professors in Immunology Immunology professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (16)

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2020

Year:

2020

Collaborators (11)

Minzhong Yu

University Hospital

UNITED STATES

View details

Lukasz P Gondek

Johns Hopkins University

UNITED STATES

View details

Challice Bonifant

Assistant Professor

Johns Hopkins University School of Medicine

UNITED STATES

View details

Jonathan Ling

Assistant Professor

Johns Hopkins University School of Medicine

UNITED STATES

View details

Saurav Haldar

Assistant Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

Céline Philippe

Université de Reims

FRANCE

View details

Tania Jain

UNITED STATES

View details

Kevin Rouault-Pierre

Senior Lecturer

Barts Cancer Institute

UNITED KINGDOM

View details

Saumya Maru

Assistant Professor

Fox Chase Cancer Center

UNITED STATES

View details

Riley Bergman

Vanderbilt University

UNITED STATES

View details

Alexander J. Ambinder

Johns Hopkins University School of Medicine

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

William Dalton

Research Interests

Explore related searches

Contact this professor

Articles (16)

Intensive chemotherapy vs venetoclax/hypomethylating agents for patients aged 60 to 75 years with favorable, NPM1-mutated AML

The E592K variant of SF3B1 creates unique RNA missplicing and associates with high-risk MDS without ring sideroblasts

Outcome heterogeneity of <i>TP53</i>-mutated myeloid neoplasms and the role of allogeneic hematopoietic cell transplantation.

An accessible patient-derived xenograft model of low-risk myelodysplastic syndromes

Tumor-derived CCL2 drives tumor growth and immunosuppression in IDH1-mutant cholangiocarcinoma

Allogeneic Blood or Marrow Transplantation with High-Dose Post-Transplantation Cyclophosphamide for Acute Lymphoblastic Leukemia in Patients Age ≥55 Years

Co-occurring mutations in ASXL1, SRSF2, and SETBP1 define a subset of myelodysplastic/ myeloproliferative neoplasm with neutrophilia

Venetoclax in combination with hypomethylating agent for the treatment of advanced myeloproliferative neoplasms and acute myeloid leukemia with extramedullary disease

CCRL2 affects the sensitivity of myelodysplastic syndrome and secondary acute myeloid leukemia cells to azacitidine.

Genomic landscape of myelodysplastic/myeloproliferative neoplasm can predict response to hypomethylating agent therapy

Nonmyeloablative Allogeneic Transplantation With Post-Transplant Cyclophosphamide for Acute Myeloid Leukemia With IDH Mutations: A Single Center Experience

Taking the STING out of acute myeloid leukemia through macrophage-mediated phagocytosis

How low risk are low risk myelodysplastic syndromes?

Cell-specific regulation of gene expression using splicing-dependent frameshifting

The metabolic reprogramming and vulnerability of SF3B1 mutations

The K666N mutation in SF3B1 is associated with increased progression of MDS and distinct RNA splicing

Collaborators (11)

Minzhong Yu

Lukasz P Gondek

Challice Bonifant

Jonathan Ling

Saurav Haldar

Céline Philippe

Tania Jain

Kevin Rouault-Pierre

Saumya Maru

Riley Bergman

Alexander J. Ambinder

Make your next move.